Swiss pharma giants who missed boat on obesity fight to stay relevant
In the Swiss city of Basel, two pharma giants face off on opposite banks of the Rhine River. But managers located a few miles apart look to be on vastly different paths to rebuild their stature.
By Naomi Kresge, Bloomberg
Roche Holding AG and Novartis AG, dealing with individual scientific, corporate and management issues, embody opposing approaches to solving a fundamental puzzle: how to placate shareholders and keep growing in an industry where the hunt for the next blockbuster drug — often long and expensive — is paramount.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Roche still deal hunting within obesity indication
For subscribers
Roche enters obesity drug race via new acquisition
For subscribers
